Log in
NASDAQ:OMCL

Omnicell Stock Forecast, Price & News

$106.57
-0.22 (-0.21 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$104.52
Now: $106.57
$109.82
50-Day Range
$79.54
MA: $90.79
$107.75
52-Week Range
$54.24
Now: $106.57
$109.82
Volume157,840 shs
Average Volume358,548 shs
Market Capitalization$4.51 billion
P/E Ratio94.31
Dividend YieldN/A
Beta0.83
Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies worldwide. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems used in hospitals and retail pharmacies for handling the stocking and retrieval of boxed medications. In addition, the company provides single dose automation solutions to fill and label for incoming prescriptions; medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings; automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; and semi-automated filling equipment for the long-term care institutional pharmacy. Further, it offers Omnicell Patient Engagement, a web-based nexus of solutions; and patient communication tools, such as interactive voice response, outbound communications, and mobile app. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.
Read More
Omnicell logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.74 out of 5 stars


Industry, Sector and Symbol

Industry Electronic computers
Sub-IndustryHealth Care Technology
SectorMedical
Current SymbolNASDAQ:OMCL
CUSIP68213N10
Phone650-251-6100
Employees2,700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$897.03 million
Cash Flow$5.11 per share
Book Value$20.16 per share

Profitability

Net Income$61.34 million

Miscellaneous

Market Cap$4.51 billion
Next Earnings Date2/4/2021 (Estimated)
OptionableOptionable
$106.57
-0.22 (-0.21 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OMCL News and Ratings via Email

Sign-up to receive the latest news and ratings for OMCL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Omnicell (NASDAQ:OMCL) Frequently Asked Questions

How has Omnicell's stock been impacted by COVID-19 (Coronavirus)?

Omnicell's stock was trading at $77.41 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, OMCL shares have increased by 37.7% and is now trading at $106.57.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Omnicell?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Omnicell
.

What stocks does MarketBeat like better than Omnicell?

Wall Street analysts have given Omnicell a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Omnicell wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Omnicell's next earnings date?

Omnicell is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Omnicell
.

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) announced its earnings results on Tuesday, October, 27th. The company reported $0.60 earnings per share for the quarter, topping analysts' consensus estimates of $0.31 by $0.29. Omnicell had a net margin of 5.42% and a return on equity of 9.21%.
View Omnicell's earnings history
.

What guidance has Omnicell issued on next quarter's earnings?

Omnicell issued an update on its fourth quarter earnings guidance on Tuesday, October, 27th. The company provided earnings per share (EPS) guidance of $0.72-0.77 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.72. The company issued revenue guidance of $238-244 million, compared to the consensus revenue estimate of $238.25 million.

What price target have analysts set for OMCL?

7 analysts have issued 1 year price targets for Omnicell's shares. Their forecasts range from $84.00 to $100.00. On average, they anticipate Omnicell's stock price to reach $93.57 in the next twelve months. This suggests that the stock has a possible downside of 12.2%.
View analysts' price targets for Omnicell
.

Who are some of Omnicell's key competitors?

What other stocks do shareholders of Omnicell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Adobe (ADBE), Micron Technology (MU), NVIDIA (NVDA), Applied Materials (AMAT), Alibaba Group (BABA) and Intel (INTC).

Who are Omnicell's key executives?

Omnicell's management team includes the following people:
  • Mr. Randall A. Lipps, Founder, Exec. Chairman, Pres & CEO (Age 63, Pay $2.28M)
  • Mr. Peter J. Kuipers, Exec. VP & CFO (Age 48, Pay $1.1M)
  • Mr. Daniel S. Johnston, Exec. VP, Chief Legal & Admin. Officer and Corp. Sec. (Age 56, Pay $859.1k)
  • Mr. Nhat H. Ngo, Exec. VP of Marketing, Strategy & Bus. Devel. (Age 47, Pay $946.09k)
  • Mr. Scott Peter Seidelmann, Exec. VP & Chief Commercial Officer (Age 44, Pay $1.05M)

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Who are Omnicell's major shareholders?

Omnicell's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.34%), Conestoga Capital Advisors LLC (3.74%), ArrowMark Colorado Holdings LLC (3.33%), State Street Corp (3.14%), Champlain Investment Partners LLC (1.38%) and First Light Asset Management LLC (0.99%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, Joanne B Bauer, Jorge R Taborga, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps and Scott Peter Seidelmann.
View institutional ownership trends for Omnicell
.

Which major investors are selling Omnicell stock?

OMCL stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc., Acadian Asset Management LLC, Scout Investments Inc., JPMorgan Chase & Co., Public Employees Retirement System of Ohio, State Street Corp, and ClariVest Asset Management LLC. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, Joanne B Bauer, Peter J Kuipers, Randall A Lipps, and Scott Peter Seidelmann.
View insider buying and selling activity for Omnicell
.

Which major investors are buying Omnicell stock?

OMCL stock was acquired by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Champlain Investment Partners LLC, First Light Asset Management LLC, Point72 Asset Management L.P., Arrowstreet Capital Limited Partnership, Conestoga Capital Advisors LLC, Federated Hermes Inc., and Pembroke Management LTD.
View insider buying and selling activity for Omnicell
.

How do I buy shares of Omnicell?

Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Omnicell's stock price today?

One share of OMCL stock can currently be purchased for approximately $106.57.

How big of a company is Omnicell?

Omnicell has a market capitalization of $4.51 billion and generates $897.03 million in revenue each year. The company earns $61.34 million in net income (profit) each year or $2.19 on an earnings per share basis. Omnicell employs 2,700 workers across the globe.

What is Omnicell's official website?

The official website for Omnicell is www.omnicell.com.

How can I contact Omnicell?

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.